IVF Abroad vs. US Clinics: Comparing SART Success Rates to $7K Greece Cycles vs. $23K American Clinics
Your clinic just quoted you $23,000. A clinic in Athens is quoting $7,000. Which one actually gets you to a baby?
If you've been pricing out your next cycle, you've probably seen the headlines by now. KFF Health News recently reported that despite promises to make fertility treatment more affordable, the average American IVF cycle still runs into the tens of thousands of dollars — and a growing number of patients are simply leaving the country. Greece, in particular, has become a destination, with clinics advertising full IVF cycles for a fraction of US prices.
I get why that's tempting. When you're staring down a second or third cycle after a failed one, and your clinic's finance office hands you a number with a comma in the middle of it, a $7,000 flight-plus-cycle package can look like the obvious answer. But here's the question almost nobody asks before booking the trip: what's the actual, SART-verified live birth rate at that price — and how does it compare to what you'd get for $23,000 at home?
Cost without a success rate attached to it isn't a price. It's a guess. And the gap between a "cheap" cycle with a low real success rate and an "expensive" cycle with a high one can flip which option is actually cheaper per baby.
Why US IVF costs so much more than a quote suggests
Before comparing international options, it helps to know what's actually inside that $23,000 US quote — because it's rarely just the retrieval and transfer. Most US clinics quote a base cycle fee that excludes medications ($4,000–$7,000), monitoring bloodwork and ultrasounds ($1,500–$3,000), PGT-A embryo testing ($3,000–$6,000), and the frozen embryo transfer you'll likely need in a separate cycle ($4,000–$6,000). I've written before about exactly how a $15K quote becomes $28K after meds, PGT, and the FET — and that math holds regardless of which country you're comparing against.
European clinics tend to bundle more of this into a single quoted price, and medication costs in the EU are often 40–60% lower due to different drug pricing regulations — which is a real, structural reason the sticker price is lower, not just marketing. That part of the KFF reporting is accurate and worth taking seriously.
What the sticker price doesn't tell you is the success rate behind it.
The SART gap: why "success rate" means something different depending on where you ask
In the US, clinics that perform IVF and want to be taken seriously report outcomes to SART (the Society for Assisted Reproductive Technology), which publishes per-clinic, age-stratified live birth rates that are audited against CDC data. It's imperfect — clinics can still cherry-pick which patients they accept, and cancelled cycles can be excluded in ways that flatter a clinic's numbers — but it's a real, standardized, third-party-verified dataset you can pull up for any US clinic before you sign anything.
Outside the US, reporting standards vary enormously by country and aren't uniformly audited the way SART data is. A clinic advertising an "85% success rate" on its website may be describing something entirely different from what SART would call a live birth rate per intended retrieval — it might be per transfer of a top-quality embryo, in patients under 35, excluding anyone who cancelled. You often can't independently verify it the way you can with a US clinic's SART report.
That doesn't mean international clinics are lying. It means you're comparing an audited number to a marketing number, and the uncertainty band around the marketing number is much wider. That uncertainty is exactly what you need to price into your decision — this is the same principle behind reading SART data correctly for your age and diagnosis at any clinic, domestic or abroad.
The math: cost per live birth, not cost per cycle
Here's the calculation that actually matters, and it's simple: divide total cost across however many cycles you'd realistically need by your cumulative probability of a live birth. That gives you cost per baby — the only number that lets you compare apples to apples.
Say you're 35. Here's how three options might actually compare across three cycles (a realistic number for many patients at this age):
| Option | Cost per cycle | Per-cycle live birth rate | Cumulative rate, 3 cycles | Total cost, 3 cycles | Effective cost per live birth |
|---|---|---|---|---|---|
| High-volume US clinic, verified SART data | $23,000 | 48% (SART-reported) | 86% | $69,000 | ~$80,000 |
| Regional US clinic, verified SART data | $16,000 | 38% (SART-reported) | 76% | $48,000 | ~$63,000 |
| Greece clinic, marketed rate | $9,000 (incl. travel) | 45% (clinic-advertised) | 83% | $27,000 | ~$32,500 |
| Greece clinic, adjusted for reporting uncertainty | $9,000 (incl. travel) | 25–35% (conservative estimate) | 58–73% | $27,000 | $37,000–$46,500 |
Cumulative probability here uses the standard formula: 1 minus (1 minus your per-cycle rate) raised to the number of cycles. So a 38% per-cycle rate over three tries is 1 − (0.62)³ = 76%.
Notice what happens at the bottom two rows. The Greece option is still the cheapest per baby even in the conservative scenario — but the range is enormous: $32,500 to $46,500, a $14,000 spread, purely because the success rate isn't independently verified. The US options have a much tighter range because SART data lets you actually pin down the real number ahead of time. You're not choosing between a known good deal and a known worse deal — you're choosing between a known number and a guess with a $14K margin of error.
This is exactly the kind of comparison Feralyx runs for you — cost per cycle, verified success rate by age and diagnosis, and cumulative probability across multiple cycles — so you're not building this table from scratch on a napkin at 11pm before a consult.
The insurance instability makes "just go abroad" more tempting than it should
Part of why international IVF is gaining traction right now isn't just the sticker price — it's that US coverage keeps shifting under patients' feet. Recent reporting from KFF Health News noted that several high-profile health industry commitments — including agreements meant to reduce insurance prior authorization burdens — were announced with fanfare but haven't actually been enforced, and are at risk of quietly disappearing. If you've dealt with a prior auth denial delaying your cycle by six weeks, you already know how much that instability costs you, both in dollars and in time you don't get back at 38. I've covered how prior authorization delays and the ERISA loophole create a $0–$35K out-of-pocket spread for patients with what looks, on paper, like identical coverage.
When your domestic coverage feels unpredictable, a flat $9,000 Greece quote with no prior auth fight attached starts to look appealing for reasons that have nothing to do with success rates. That's a legitimate factor — just make sure you're weighing it against the verified-data gap above, not instead of it.
What to actually ask before you book anything — domestic or abroad
If you're seriously comparing clinics, whether across town or across an ocean, get the same five numbers from each one before you decide anything:
- Per-cycle live birth rate for your exact age bracket and diagnosis — not an overall clinic average, which can mask a lot.
- Whether that rate is per retrieval or per transfer — these numbers can differ by 15–20 percentage points and clinics know which one sounds better.
- Cancellation rate — a clinic that cancels a lot of cycles before retrieval can post an artificially high "success rate" among the cycles that make it to transfer.
- All-in cost including meds, monitoring, PGT-A, and a likely FET — not just the base cycle fee.
- Independent verification of the reported rate — SART for US clinics; for international clinics, ask directly whether they report to a national or regional registry (like ESHRE in Europe) and request that data, not just the website figure.
If a clinic — anywhere — won't give you a straight answer on all five, that's information too.
Run your own numbers before your next cycle
The spread between a $23,000 quote and a $7,000 quote feels enormous until you divide by your actual probability of a live birth — and then it either gets bigger or nearly disappears, depending on the real numbers behind each price. You can model this for your specific age, diagnosis, insurance situation, and the specific clinics you're considering — domestic or international — at Feralyx, rather than trying to reconstruct SART tables and cumulative probability math by hand during an already exhausting decision.
You've already done the hardest part of this — surviving the cycles, the waiting, the numbers on a screen that don't mean what you hoped. Comparing clinics with your actual data shouldn't be the part that breaks you. Feralyx exists so it isn't.
Sources
- High Fertility Costs Push Americans Abroad for IVF Treatment — KFF Reproductive Health
- With Midterms Looming, Journalists Consider Measles, Food Recalls, and Obamacare — KFF Reproductive Health
- Why Older Pedestrians Fare Worse in Car Crashes — KFF Reproductive Health
- Listen to the Latest ‘KFF Health News Minute’ — KFF Reproductive Health
- Trump and Kennedy’s Health Industry Deals Haven’t Been Enforced and Are at Risk of Vanishing — KFF Reproductive Health